Literature DB >> 20420251

Risk factors and clinicopathological study of prognostic factors in the peritoneal mesothelioma.

Edward C G Tudor1, Terence C Chua, Winston Liauw, David L Morris.   

Abstract

This study evaluates the clinical and treatment related prognostic indicators for survival of patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma. We did an observational study of the risk factors and clinicopathological factors of 20 patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma at the St George Hospital, Sydney. Survival analysis was performed using the Kaplan-Meier method and prognostic factors were correlated with survival using the Log Rank test. There were six females. The mean age was 55 years. The overall median survival was 30 (0.5-87) months with 1- and 3-year survival of 78 per cent and 46 per cent, respectively. The overall median disease-free survival was 8 months. Factors influencing a longer disease-free survival included age > or = 55 (P = 0.006), not smoking (P = 0.04), female (P = 0.03), and epithelioid tumors (P = 0.002). Overall survival was influenced by not consuming alcohol (P = 0.003), complete cytoreduction (P = 0.02), and epithelioid tumors (P = 0.01). Risk factors identified to be prognostic for survival include the female gender, not smoking, not consuming alcohol, and an epithelioid tumor type. Treatment factor associated with an improved survival was a complete cytoreduction.

Entities:  

Mesh:

Year:  2010        PMID: 20420251

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  3 in total

1.  Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma.

Authors:  Aaron U Blackham; Edward A Levine
Journal:  European J Clin Med Oncol       Date:  2012-07

2.  Does the expression of BCL2 have prognostic significance in malignant peritoneal mesothelioma?

Authors:  Krishna Pillai; Mohammad H Pourgholami; Terence C Chua; David L Morris
Journal:  Am J Cancer Res       Date:  2013-06-20       Impact factor: 6.166

3.  Exemestane blocks mesothelioma growth through downregulation of cAMP, pCREB and CD44 implicating new treatment option in patients affected by this disease.

Authors:  Barbara Nuvoli; Sabrina Germoni; Carlotta Morosetti; Raffaela Santoro; Giancarlo Cortese; Serena Masi; Iole Cordone; Rossella Galati
Journal:  Mol Cancer       Date:  2014-03-21       Impact factor: 27.401

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.